-+ 0.00%
-+ 0.00%
-+ 0.00%

Helus Pharma Presents Four Posters Evaluating HLP003 To Treat Major Depressive Disorder At Psych Congress 2026

Benzinga·09/21/2026 11:38:32
Listen to the news

Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026, September 15–19, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.